

1 Supplementary Table 1. Search strategy used for MEDLINE

Database: Ovid MEDLINE® and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 1946 to August 07, 2020	
#	Searches
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	exp Betacoronavirus/
4	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or sudden acute respiratory syndrome*).tw,kf.
5	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kf.
6	(pneumonia.tw,kf. Or exp pneumonia/) and (Wuhan or Hubei).tw,kf.
7	COVID-19.rx,px,ox. Or severe acute respiratory syndrome coronavirus 2.os.
8	exp Influenza A Virus, H1N1 Subtype/
9	("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kf.
10	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab sample*" or "flocked swab*").tw,kf.
12	Nasal cavity/vi
13	Sputum/vi
14	Nasopharynx/vi
15	Oropharynx/vi
16	*Saliva/vi
17	Pharynx/vi
18	(clinical adj2 (sample* or specimen*)).tw,kf.
19	("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kf.
20	Influenza, Human/vi
21	exp Coronavirus Infections/vi or exp Coronavirus/vi or exp Betacoronavirus/vi

22	polymerase chain reaction/ or multiplex polymerase chain reaction/ or real-time polymerase chain reaction/ or reverse transcriptase polymerase chain reaction/
23	11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24	10 and 23
25	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kf.
26	((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*).tw,kf.
27	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kf.
28	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*).tw,kf.
29	Viral load/
30	Viral shedding/
31	("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kf.
32	((test or diagnos*) adj2 sensitiv*).tw,kf.
33	25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34	24 and 33
35	animals/ not humans/
36	34 not 35

2

3 Supplementary Table 2. Search strategy used for EMBASE

Database: Embase 1974 to 2020 August 06	
#	Searches
1	coronavirus infection/ or severe acute respiratory syndrome/
2	COVID 19/
3	coronavirus disease 2019/
4	severe acute respiratory syndrome coronavirus 2/ or SARS coronavirus 2/
5	SARS coronavirus/ or betacoronavirus/
6	“influenza a virus (h1n1)”/
7	2009 h1n1 influenza/ or “influenza a (h1n1)”/
8	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or Sudden acute respiratory syndrome*).tw,kw.
9	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kw.
10	(pneumonia.tw,kw. Or exp pneumonia/) and (Wuhan or Hubei).tw,kw.
11	(covid or SARS or H1N1 or coronavirus).ox.
12	(“A/H1N1*” or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 “2009”) or influenza A or swine flu).tw,kw.
13	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14	nose smear/
15	smear/ or nose smear/ or sputum smear/
16	*sputum/
17	*nasopharynx/ or *pharynx/
18	throat culture/
19	saliva analysis/
20	*oropharynx/
21	exp nasopharyngeal aspiration/
22	real time polymerase chain reaction/ or real time reverse transcription polymerase chain reaction/ or reverse transcription polymerase chain reaction/
23	(clinical adj2 (sample* or specimen*)).tw,kw.
24	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or “swab sample*” or “flocked swab*”).tw,kw.
25	(“RT-PCR” or “RTPCR” or “ddPCR” or “polymerase chain reaction”).tw,kw.
26	*2009 H1N1 influenza/di or coronavirus disease 2019/di or Coronavirus infection/di
27	14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26

28	13 and 27
29	virus load/
30	virus shedding/
31	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kw.
32	(((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*)).tw,kw.
33	((calibration adj1 curve* or (standard adj1 curve*)).tw,kw.
34	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kw.
35	("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kw.
36	((test or diagnos*) adj2 sensitiv*).tw,kw.
37	29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38	28 and 37
39	exp animal/ not human/
40	38 not 39

4

5 Supplementary Table 3. Search strategy used for Cochrane Central

Database(s): EBM Reviews – Cochrane Central Register of Controlled Trials July 2020	
#	Searches
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	betacoronavirus/
4	(coronavirus* or corona virus* or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome* or sudden acute respiratory syndrome*).tw,kw.
5	(2019nCov* or 2019-novel CoV or corona or covid19 or ((novel or new or nouveau) adj2 (CoV or Pandemi*))).tw,kw.
6	(pneumonia.tw,kw. Or exp pneumonia/) and (Wuhan or Hubei).tw,kw.
7	exp Influenza A Virus, H1N1 Subtype/
8	("A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) adj4 "2009") or influenza A or swine flu).tw,kw.
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10	((respiratory adj3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) adj3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) adj2 aspirat*) or NPA or ETA or (deep adj4 saliva) or POS or "swab sample*" or "flocked swab*").tw,kw.
11	Nasal cavity/
12	Sputum/
13	Nasopharynx/
14	Oropharynx/
15	*Saliva/
16	Pharynx/
17	(clinical adj2 (sample* or specimen*)).tw,kw.
18	("RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction").tw,kw.
19	exp Coronavirus Infections/vi or exp Coronavirus/vi or exp Betacoronavirus/vi
20	polymerase chain reaction/ or multiplex polymerase chain reaction/ or real-time polymerase chain reaction/ or reverse transcriptase polymerase chain reaction/
21	10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22	9 and 21
23	(vir* load* or vir* shed* or vir* burden or vir* titer* or vir* titre* or (vir* adj2 count*)).tw,kw.
24	((((copies or copy) adj2 (ml* or milli* or microl*)) or ((RNA* or vir*) adj2 concentration*))).tw,kw.
25	((calibration adj1 curve*) or (standard adj1 curve*)).tw,kw.
26	((ct* adj1 value*) or cycle threshold or (copies adj2 test*) or (copy adj2 test*) or ((copy or copies) adj2 number*)).tw,kw.
27	Viral load/

28	Viral shedding/
29	("copy/m*" or "copies/m*" or "copy/test*" or "copies/test*").tw,kw.
30	((test or diagnos* adj2 sensitiv*).tw,kw.
31	23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32	22 and 31

6

7 **Supplementary Table 4. Search strategy used for Web of Science Core Collection**

Web of Science Core Collection	
#	Searches
#1	<p>TOPIC: ((coronavirus* or "corona virus*" or betacoronavirus* or OC43 or NL63 or 229E or HKU1 or HcoV* or ncov* or covid* or "sars-cov*" or sarscov* or "Sars-coronavirus*" or "Severe Acute Respiratory Syndrome*" or "sudden acute respiratory syndrome*" or "2019-ncov*" or 2019nCov* or "2019-novel CoV" or corona or ((novel or new or nouveau) NEAR/2 (CoV or Pandemi*)) OR (pneumonia and (Wuhan or Hubei)) or "A/H1N1*" or H1N1* or pdm09 or ((influenza or virus or pandemic) NEAR/4 "2009") or "influenza A" or "swine flu"))</p> <p>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</p>
#2	<p>TOPIC: (((respiratory NEAR/3 (specimen* or sample* or swab*)) or sputum or nares or endotrachea* or endotrache* or endotra* or ((nasal or oral* or throat) NEAR/3 (swab* or sample* or smear* or specimen*)) or NPS or OPS or ((endotrachea* or endotracheal*) NEAR/2 aspirat*) or NPA or ETA or (deep NEAR/4 saliva) or POS or "swab sample*" or "flocked swab*" or (clinical NEAR/2 (sample* or specimen*)) or "RT-PCR" or "RTPCR" or "ddPCR" or "polymerase chain reaction"))</p> <p>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</p>
#3	<p>TOPIC: (("vir* load*" or "vir* shed*" or "vir* burden" or "vir* titer*" or "vir* titre*" or (vir* NEAR/2 count*) or ((copies or copy) NEAR/2 (ml or mls or milli* or microl*)) or ((RNA* or vir*) NEAR/2 concentration*) or (calibration NEAR/1 curve*) or (standard NEAR/1 curve*) or "ct value*" or "cycle threshold" or ((copies or copy) NEAR/2 test*) or ((copy or copies) NEAR/2 number*) or "copy/m*" or "copies/m*" or "copy/test*" or "copies/test*" or ((test or diagnos*) NEAR/2 sensitiv*))</p> <p>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</p>
#4	<p>#3 AND #2 AND #1</p> <p>Refined by: [excluding] WEB OF SCIENCE CATEGORIES: (VETERINARY SCIENCES)</p> <p>Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</p>

8

9 **Supplementary Table 5. Search strategy used for medRxiv and bioRxiv**

medRxiv + bioRxiv (via Publish or Perish program)
Keywords: (covid OR coronavirus OR ncov OR hcov OR h1n1 OR “swine flu” OR COVID19 or SARS) AND (“copies/ml” OR “copy/ml” OR “viral load” OR “copies/test” OR “copy/test” OR “copies per ml” OR “copy per ml”)
Publication name: MedRxiv
Keywords: (covid OR coronavirus OR ncov OR hcov OR h1n1 OR “swine flu” OR COVID19 or SARS) AND (“copies/ml” OR “copy/ml” OR “viral load” OR “copies/test” OR “copy/test” OR “copies per ml” OR “copy per ml”)
Publication name: BioRxiv

10

11 **Supplementary Table 6. Summary of risk of bias assessment based on the hybrid JBI**
 12 **critical appraisal checklist**

Study†	Checklist items*									
	1	2	3	4	5	6	7	8	9	10
Argyropoulos et al. ⁵⁷	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Baggio et al. ⁵⁵	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Fajnzylber et al. ⁴⁷	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Han et al. ⁶⁵	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Han et al. ⁶³	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Hung et al. ⁵²	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Hurst et al. ⁶¹	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Iwasaki et al. ⁵³	Yellow	Red	Yellow	Green	Red	Green	Green	Red	Green	Green
Kawasuji et al. ⁶⁶	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
L'Huillier et al. ⁶²	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Lavezzo et al. ⁴³	Green	Green	Red	Green	Red	Green	Green	Red	Green	Green
Lennon et al. ⁴⁹	Red	Green	Green	Green	Red	Green	Green	Red	Green	Green
Lucas et al. ⁵⁶	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
Mitja et al. ⁵⁸	Red	Green	Green	Green	Red	Green	Green	Red	Green	Green
Pan et al. ⁶⁴	Green	Red	Yellow	Green	Red	Green	Green	Red	Green	Green
Peng et al. ⁴⁴	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Perera et al. ⁵⁴	Green	Red	Yellow	Green	Red	Green	Green	Red	Green	Green
Shi et al. ⁵¹	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
Shrestha et al. ⁵⁰	Red	Green	Green	Green	Red	Green	Green	Red	Green	Green
To et al. ⁴⁵	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
van Kampen et al. ³⁵	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Vetter et al. ⁵⁹	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Wölfel et al. ¹³	Green	Green	Red	Yellow	Red	Green	Green	Red	Green	Green
Xu et al. ⁶⁰	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Zhang et al. ⁴²	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Zheng et al. ⁴⁸	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Zou et al. ⁴⁶	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Chen et al. ⁶⁹	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Chu et al. ⁶⁷	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Chu et al. ⁷⁰	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Chu et al. ⁷²	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Cheng et al. ⁷⁴	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Hung et al. ⁷³	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
Peiris et al. ⁷⁵	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Poon et al. ⁶⁸	Green	Red	Yellow	Green	Red	Green	Green	Red	Green	Green
Poon et al. ⁷¹	Green	Red	Yellow	Green	Red	Green	Green	Red	Green	Green
Alves et al. ⁹⁸	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Chan et al. ⁸⁸	Green	Red	Yellow	Green	Red	Green	Green	Red	Green	Green
Cheng et al. ⁹⁹	Green	Red	Yellow	Green	Red	Green	Green	Red	Green	Green
Cowling et al. ⁹⁶	Green	Green	Red	Yellow	Red	Green	Green	Red	Green	Green
Duchamp et al. ¹⁰¹	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Esposito et al. ⁹⁴	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
Hung et al. ⁸⁹	Red	Green	Green	Green	Red	Green	Green	Red	Green	Green
Ip et al. ⁸⁰	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Ito et al. ⁹²	Green	Red	Yellow	Green	Red	Green	Green	Red	Green	Green
Killingley et al. ⁸⁶	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Launes et al. ⁸⁵	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Lee et al. ⁸⁷	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
Lee et al. ⁹⁵	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Li et al. ⁷⁸	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
Li et al. ⁹³	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
Loeb et al. ⁷⁶	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Lu et al. ⁷⁹	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Meschi et al. ⁸²	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Ngaosuwanukul et al. ¹⁰⁰	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
Rath et al. ⁸¹	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Suess et al. ⁷⁷	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Thai et al. ⁹¹	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
To et al. ⁹⁰	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
To et al. ⁹⁷	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
Watanabe et al. ¹⁰²	Green	Green	Green	Green	Red	Green	Green	Red	Green	Green
Wu et al. ⁸³	Green	Green	Yellow	Green	Red	Green	Green	Red	Green	Green
Yang et al. ⁸⁴	Green	Red	Yellow	Green	Red	Green	Green	Red	Green	Green

*Descriptions of each item are included in the hybrid JBI critical appraisal checklist (shown in Supplementary Notes). Green, yellow and red represent yes, unclear and no, respectively.

†References 13 and 35 are listed in the main body while those 42 and after are listed in Methods.

13
14
15

16 **Supplementary Notes. Hybrid JBI critical appraisal checklist**

17 Reviewer _____ Date _____

18
19 Author _____ Year _____ Record Number _____

	Yes	No	Unclear	Not applicable
1. Was the sample frame appropriate to address the target population?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Were the study subjects and the setting described in detail?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Did the study have consecutive inclusion of participants for case series and cohort studies? Did the study use probability-based sampling for cross-sectional studies?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Was the response rate adequate, and if not, was the low response rate managed appropriately?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Was the sample size adequate?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were valid methods used for the identification of the condition?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were standard, valid methods used for measurement of the exposure?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Was the exposure measured in an objective, reliable way for all participants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Was there clear reporting of clinical information of the participants?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Was statistical analysis appropriate?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

21 Overall appraisal: Include Exclude Seek further info

22 Comments (Including reason for exclusion)

23 _____

24 _____

25 _____

26 Tool Guidance

27 Answers: Yes, No, Unclear or Not/Applicable

28 This hybrid checklist was based on the JBI Critical Appraisal Checklists for case series, prevalence
29 studies and analytical cross-sectional studies.

30

31 1. **Was the sample frame appropriate to address the target population?**

32 This question relies upon knowledge of the broader characteristics of the population of
33 interest and the geographical area.

34 This study broadly investigates the respiratory viral load for the diseases of interest. The
35 population of interest is the general population infected with SARS-CoV-2, SARS-CoV-1, or
36 A(H1N1)pdm09. The geographical area is not constrained. Sample frames restricted to
37 particular subgroups within the general infected population were considered appropriate
38 if they targeted one of the following groups analysed in our study: asymptomatic,
39 presymptomatic, symptomatic, adult, pediatric, hospitalized, non-hospitalized, or
40 community.

41

42 2. **Were the study subjects and the setting described in detail?**

43 Certain diseases or conditions vary in prevalence across different geographic regions and
44 populations (e.g. Women vs. Men, sociodemographic variables between countries). The
45 study sample should be described in sufficient detail so that other researchers can
46 determine if it is comparable to the population of interest to them

47

48 3. **Did the study have consecutive inclusion of participants for case series and cohort 49 studies? Did the study use probability sampling for cross-sectional studies?**

50 Inclusion of consecutive participants for case series and cohort studies yields results at
51 lower risk of bias compared to other sampling methods for these study designs. Use of
52 probability-based sampling methods for cross-sectional studies yields estimates at lower
53 risk of bias compared to other sampling methods for this design. Studies that indicate a
54 consecutive inclusion are more reliable than those that do not. For example, a case series
55 that states 'we included all patients (24) with osteosarcoma who presented to our clinic
56 between March 2005 and June 2006' is more reliable than a study that simply states 'we
57 report a case series of 24 people with osteosarcoma.'

58

59 4. **Was the response rate adequate, and if not, was the low response rate managed 60 appropriately?**

61 A large number of dropouts, refusals or “not founds” amongst selected subjects may
62 diminish a study’s validity, as can a low response rates for survey studies. The authors
63 should clearly discuss the response rate and any reasons for non-response and compare
64 persons in the study to those not in the study, particularly with regards to their socio-
65 demographic characteristics. If reasons for non-response appear to be unrelated to the
66 outcome measured and the characteristics of non-responders are comparable to those
67 who do respond in the study, the researchers may be able to justify a more modest
68 response rate.

69

70 **5. Was the sample size adequate?**

71 The larger the sample, the narrower will be the confidence interval around the prevalence
72 estimate, making the results more precise. An adequate sample size is important to ensure
73 good precision of the final estimate. The sample size threshold was calculated as follows:

74
$$n^* = z^2 \sigma / d^2$$

75 where n^* is the sample size threshold, z is the z-score for the level of confidence (95%), σ
76 is the standard deviation (assumed to be 3 log₁₀ copies/ml, a fourth of the full range of
77 rVLs) and d is the marginal error (assumed to be 1 log₁₀ copies/ml, based on the minimum
78 detection limit for qRT-PCR across studies). This item was met if ≥75% of the included DFSO
79 had ≥46 specimen measurements.

80

81 **6. Were valid methods used for the identification of the condition?**

82 Many health problems are not easily diagnosed or defined and some measures may not
83 be capable of including or excluding appropriate levels or stages of the health problem. If
84 the outcomes were assessed based on existing definitions or diagnostic criteria, then the
85 answer to this question is likely to be yes. If the outcomes were assessed using observer
86 reported, or self-reported scales, the risk of over- or under-reporting is increased, and
87 objectivity is compromised. Importantly, determine if the measurement tools used were
88 validated instruments as this has a significant impact on outcome assessment validity.

89

90 **7. Were standard, valid methods used for measurement of the exposure?**

91 The study should clearly describe the method of measurement of exposure. Assessing
92 validity requires that a 'gold standard' is available to which the measure can be
93 compared. The validity of exposure measurement usually relates to whether a current
94 measure is appropriate or whether a measure of past exposure is needed.

95 In this study, standard methods to measure viral load in respiratory specimens are RT-
96 PCR quantifying via one of the standard genes for each virus.

97

- 98 **8. Was the exposure measured in an objective, reliable way for all participants?**
99 The study should clearly describe the procedural aspects of the measurement of
100 exposure as well as factors that can contribute to heterogeneity in measurement.
101 In this study, objective, reliable interpretation of the exposure depends on the use of
102 quantitative calibration; the specification of extraction; determination of the viral load as
103 a standard metric (e.g., copies/ml or equivalent) or in a manner that can be converted to
104 a standard metric; and, if present, specification of the amount of diluent (e.g., viral
105 transport media) used.
106
- 107 **9. Was there clear reporting of clinical information of the participants?**
108 There should be clear reporting of clinical information of the participants such as the
109 following information where relevant: disease status, comorbidities, stage of disease,
110 previous interventions/treatment, results of diagnostic tests, etc.
111 In addition, there should be clear reporting of the number and types (asymptomatic,
112 presymptomatic, symptomatic, adult, pediatric, hospitalized, non-hospitalized,
113 community, etc.) of cases for measurements within the sampling periods of interest. For
114 studies that include data outside of the infectious period, there should be clear reporting
115 of clinical information for participants for the specimen measurements that were
116 collected from within the infectious period.
117
- 118 **10. Was statistical analysis appropriate?**
119 As with any consideration of statistical analysis, consideration should be given to whether
120 there was a more appropriate alternate statistical method that could have been used.
121 The methods section of studies should be detailed enough for reviewers to identify which
122 analytical techniques were used and whether these were suitable.